475 Shares in IDEXX Laboratories, Inc. $IDXX Acquired by Grunden Financial Advisory Inc.

Grunden Financial Advisory Inc. purchased a new position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 475 shares of the company's stock, valued at approximately $255,000. IDEXX Laboratories makes up 0.1% of Grunden Financial Advisory Inc.'s portfolio, making the stock its 27th largest position.

Several other large investors have also made changes to their positions in IDXX. MorganRosel Wealth Management LLC acquired a new stake in shares of IDEXX Laboratories during the 1st quarter worth approximately $26,000. Opal Wealth Advisors LLC acquired a new stake in shares of IDEXX Laboratories during the 2nd quarter worth approximately $29,000. Migdal Insurance & Financial Holdings Ltd. lifted its stake in IDEXX Laboratories by 55.6% in the 1st quarter. Migdal Insurance & Financial Holdings Ltd. now owns 84 shares of the company's stock valued at $35,000 after purchasing an additional 30 shares during the last quarter. Ameritas Advisory Services LLC bought a new position in IDEXX Laboratories in the 2nd quarter valued at approximately $36,000. Finally, WPG Advisers LLC bought a new position in IDEXX Laboratories in the 1st quarter valued at approximately $37,000. Institutional investors and hedge funds own 87.84% of the company's stock.

Insider Buying and Selling at IDEXX Laboratories

In related news, Director M Anne Szostak sold 2,187 shares of IDEXX Laboratories stock in a transaction on Friday, August 22nd. The shares were sold at an average price of $647.33, for a total transaction of $1,415,710.71. Following the completion of the transaction, the director owned 262 shares of the company's stock, valued at $169,600.46. This trade represents a 89.30% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jonathan Jay Mazelsky sold 29,260 shares of IDEXX Laboratories stock in a transaction on Wednesday, August 6th. The stock was sold at an average price of $631.98, for a total transaction of $18,491,734.80. Following the transaction, the chief executive officer directly owned 83,311 shares of the company's stock, valued at $52,650,885.78. This represents a 25.99% decrease in their position. The disclosure for this sale can be found here. Insiders have sold 54,057 shares of company stock valued at $34,293,468 over the last three months. 0.98% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts recently commented on the stock. Leerink Partners increased their price objective on shares of IDEXX Laboratories from $580.00 to $600.00 and gave the company an "outperform" rating in a research note on Thursday, July 17th. Weiss Ratings reissued a "buy (b-)" rating on shares of IDEXX Laboratories in a research note on Wednesday, October 8th. Morgan Stanley increased their price objective on shares of IDEXX Laboratories from $722.00 to $765.00 and gave the company an "overweight" rating in a research note on Friday, August 15th. Stifel Nicolaus set a $640.00 price objective on shares of IDEXX Laboratories in a research note on Monday, August 4th. Finally, BTIG Research increased their price objective on shares of IDEXX Laboratories from $545.00 to $785.00 and gave the company a "buy" rating in a research note on Tuesday, August 5th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, the stock currently has an average rating of "Moderate Buy" and a consensus target price of $656.50.

IDEXX Laboratories Price Performance

IDXX stock opened at $635.40 on Monday. The company has a fifty day moving average price of $639.99 and a 200-day moving average price of $551.18. The company has a market capitalization of $50.83 billion, a P/E ratio of 52.91, a PEG ratio of 4.11 and a beta of 1.58. IDEXX Laboratories, Inc. has a 52-week low of $356.14 and a 52-week high of $688.12. The company has a debt-to-equity ratio of 0.31, a quick ratio of 0.79 and a current ratio of 1.11.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its quarterly earnings results on Monday, August 4th. The company reported $3.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.28 by $0.35. The firm had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.06 billion. IDEXX Laboratories had a net margin of 24.41% and a return on equity of 64.42%. The company's revenue for the quarter was up 10.6% on a year-over-year basis. During the same quarter last year, the firm earned $2.44 earnings per share. IDEXX Laboratories has set its FY 2025 guidance at 12.400-12.760 EPS. As a group, equities analysts expect that IDEXX Laboratories, Inc. will post 11.93 EPS for the current year.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.